UnitedHealth Group reported strong second-quarter results, with double-digit revenue growth across Optum and UnitedHealthcare. Management increased their adjusted EPS outlook for the year, highlighting sustained momentum and growth across all business segments. The positive performance and raised guidance are likely to have a positive short-term impact on the stock price.

[1]